Press Release

Global Idiopathic Pulmonary Fibrosis Market to grow with a CAGR of 5.94%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Idiopathic Pulmonary Fibrosis Market.

 

According to TechSci Research report, “Global Idiopathic Pulmonary Fibrosis Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Idiopathic Pulmonary Fibrosis Market has valued at USD 2.25 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.94% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. Awareness and education play a crucial role in driving the demand for the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Increased awareness and education about IPF symptoms and risk factors can lead to earlier diagnosis. Early diagnosis is associated with better treatment outcomes, and patients may seek medical attention sooner if they are aware of the disease. Informed patients are more likely to seek medical advice and ask healthcare providers about IPF. This can lead to increased patient demand for diagnostic tests and therapies. Education about the importance of treatment and adherence to prescribed therapies can lead to better patient compliance. Patients who understand their condition and treatment regimens are more likely to follow them closely. Greater awareness can lead to increased public and private sector funding for IPF research. More funding supports research initiatives to develop new therapies and diagnostic tools, driving demand in the research and development sector. Awareness campaigns often involve patient advocacy groups that work to raise awareness about IPF. These groups may advocate for better access to care and increased research funding, which can drive demand for related products and services. Increased awareness among healthcare providers can lead to more accurate and timely diagnoses of IPF. This can generate demand for diagnostic tools and consultations with specialists.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Idiopathic Pulmonary Fibrosis Market.”

 

 Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease characterized by the progressive thickening and stiffening of lung tissues over time. This thickening restricts the lungs' ability to effectively oxygenate the bloodstream, impacting oxygen delivery to vital organs, including the brain. IPF leads to the accumulation of scar tissue (fibrosis) in the lungs, further hampering the efficient transport of oxygen. This condition primarily affects individuals in the age range of 50 to 70. IPF is categorized under a group of conditions known as interstitial lung diseases (ILD), which encompass lung disorders involving inflammation or scarring within the lung tissue. In May 2023, Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug Application (IND) related to a Phase II study focusing on patients with Idiopathic Pulmonary Fibrosis, which is the most common form of progressive fibrosing interstitial lung disease. Consequently, Cumberland is set to initiate its FIGHTING FIBROSIS trial, with plans to enroll 128 patients across more than 20 leading medical centres in the United States. In this development, Idiopathic Pulmonary Fibrosis (IPF) emerges as the latest addition to Cumberland's clinical program, involving their first new chemical entity, ifetroban – a powerful and selective thromboxane receptor antagonist. The company has devised a Phase II clinical trial aimed at assessing the safety, tolerability, and effectiveness of oral ifetroban in patients with IPF. Recent research has demonstrated ifetroban's ability to both prevent and promote the resolution of lung fibrosis in various preclinical models.

Healthcare disparities are a significant challenge in the Global Idiopathic Pulmonary Fibrosis (IPF) Market. Healthcare disparities refer to differences in healthcare access, quality of care, and health outcomes among various population groups. These disparities can impact the diagnosis, treatment, and overall care of individuals with IPF. Patients from underserved or marginalized communities may face barriers to accessing healthcare services, leading to delayed diagnosis and treatment initiation. This delay can impact disease prognosis. IPF is a complex and rare lung disease that often requires specialized care from pulmonologists and healthcare centers experienced in managing the condition. Disparities in access to specialized care can lead to suboptimal treatment. Geographic disparities can affect access to healthcare services. Patients in rural or remote areas may have limited access to healthcare facilities and specialists, impacting their ability to receive timely and quality care. Socioeconomic disparities, including income, education, and insurance status, can influence the type and quality of care received.

Patients with limited financial resources may face difficulties in accessing expensive medications and therapies. Racial and ethnic minorities may experience disparities in IPF care. These disparities can be related to access to care, cultural factors, and bias within the healthcare system.  IPF is more common in men, and gender-related disparities can affect the care received by female patients. Women with IPF may face challenges in diagnosis and access to treatment options. Language barriers can hinder communication between healthcare providers and patients, potentially leading to misunderstandings about the diagnosis and treatment of IPF.

Global Idiopathic Pulmonary Fibrosis Market is segmented based on Drug Type, Route of Administration, Distribution Channel, and by region.  Based on the Drug Type, Global Idiopathic Pulmonary Fibrosis Market is segmented into Pirfenidone, Nintedanib, and others. Nintedanib is a medication used in the treatment of various pulmonary and fibrotic diseases, with one of its primary applications being in the management of Idiopathic Pulmonary Fibrosis (IPF). Nintedanib is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease characterized by the scarring of lung tissue. It is used to slow the progression of the disease. Nintedanib is classified as a tyrosine kinase inhibitor. It works by blocking specific signaling pathways that play a role in the formation of fibrotic tissue in the lungs. By inhibiting these pathways, Nintedanib can help slow down the scarring process, which is a hallmark of IPF. Nintedanib is used as a disease-modifying therapy for IPF. It is not a cure, but it can help slow the decline in lung function and improve the quality of life for individuals with IPF. Nintedanib is typically taken orally in the form of capsules. The recommended dosage and treatment duration are determined by a healthcare provider based on the individual's condition and medical history.

Based on Region, North America held the largest share in the Global Idiopathic Pulmonary Fibrosis Market. North America has a relatively high prevalence of IPF, with a significant number of patients in the region. This, in turn, creates a substantial market for IPF-related products and services. The regulatory environment in North America is generally conducive to the development and marketing of new therapies for rare and serious diseases like IPF. North America is home to several patient advocacy groups and organizations dedicated to supporting those with IPF. These groups play a role in raising awareness, promoting research, and providing resources for patients. The region hosts research institutions, academic centers, and medical universities that actively engage in IPF research and collaborate with the pharmaceutical industry to develop and test new treatments.

 

Some of the major companies operating in the Global Idiopathic Pulmonary Fibrosis Market include:

  • Boehringer Ingelheim
  • F. Hoffmann-La Roche AG
  • Cipla Ltd.
  • Shionogi & Co., Ltd.
  • Bristol-Myers Squibb Co.
  • United Therapeutics
  • FibroGen, Inc.
  • Pliant Therapeutics
  • Galecto Inc.
  • CSL Behring

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Certain areas, particularly in North America, are projected to exert significant demand for Idiopathic Pulmonary Fibrosis treatment. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Idiopathic Pulmonary Fibrosis Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, others), By Route of Administration (Parenteral, Oral, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Idiopathic Pulmonary Fibrosis Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Idiopathic Pulmonary Fibrosis Market.


 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com

Relevant News